Journal
MOLECULAR BIOLOGY REPORTS
Volume 41, Issue 1, Pages 233-240Publisher
SPRINGER
DOI: 10.1007/s11033-013-2856-0
Keywords
Transcription factors; Genetic alterations; Signalling pathways; survivin gene; Transcription regulation
Categories
Funding
- Ligue contre le Cancer de Cote d'Or and Ligue contre le Cancer de l'Yonne
- Ligue nationale contre le Cancer
Ask authors/readers for more resources
Survivin, a small member of the inhibitors of the apoptosis protein family, is highly deregulated in cancer. It is weakly expressed in normal tissues but very strongly expressed in malignant lesions. Survivin is involved in cell-cycle progression, especially in the G2/M transition, and has anti-apoptotic activity, which correlates with its strong expression in cases with a poor cancer treatment response and poor outcomes. Several therapies that target the survivin transcript or protein are currently being tested in clinical trials. However, focusing new therapies on the origins of survivin overexpression and targeting these upstream deregulations could be more effective. For this reason, it seems important to make an inventory of the transcriptional (de)regulation of survivin. This review will gather the important points concerning the regulation of survivin mRNA expression: structure of the survivin promoter, epigenetic modifications and genetic abnormalities, transcription factors, and signalling pathways that affect survivin mRNA expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available